Clinical Trials
28 trialsNCT06570031 2026-06-05
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT05386108 2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05768139 2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07174336 2026-06-04
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT03939897 2026-06-01
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06830720 2026-06-01
CAROLEEN
Novartis
Recruiting
NCT05952557 2026-05-28
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT06678269 2026-05-28
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04523857 2026-05-26
ABBY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT07340541 2026-05-20
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06760637 2026-05-19
FourLight-3
Pfizer
Phase 3 Active not recruiting
NCT07100106 2026-05-18
MoonROSE
Genentech, Inc.
Phase 1/2 Recruiting
NCT05372640 2026-05-13
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT04305834 2026-05-04
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
Phase 2 Recruiting
NCT03616587 2026-04-30
SERENA-1
AstraZeneca
Phase 1 Active not recruiting
NCT05608252 2026-04-30
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT03155997 2026-04-24
monarchE
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04964934 2026-04-21
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT05696626 2026-04-21
ELAINEIII
LeonaBio
Phase 3 Recruiting
NCT05307705 2026-04-20
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04920708 2026-04-14
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT05095207 2026-04-13
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT05735080 2026-04-01
INX-315-01
Incyclix Bio
Phase 1/2 Recruiting
NCT04791384 2026-03-31
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Terminated
NCT07487129 2026-03-23
Clinical and P
Beni-Suef University
Phase 4 Completed
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting